Inventiva S.A.
Inventiva S.A. (IVA) Stock Competitors & Peer Comparison
See (IVA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IVA | $5.16 | +1.78% | 268.2M | -2.33 | -$2.21 | N/A |
| NVO | $44.19 | -1.71% | 196.4B | 10.38 | $4.26 | +4.06% |
| VRTX | $435.93 | +0.32% | 110.6B | 25.86 | $16.86 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $634.62 | -0.67% | 65.4B | 15.50 | $40.95 | +0.57% |
| ARGX | $808.43 | +0.24% | 50B | 35.93 | $22.50 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $295.50 | -0.66% | 39.5B | 74.08 | $3.99 | N/A |
| RVMD | $154.89 | +2.20% | 32.9B | -21.76 | -$7.11 | N/A |
| UTHR | $578.43 | +1.76% | 24.6B | 21.39 | $27.06 | N/A |
Stock Comparison
IVA vs NVO Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, NVO has a market cap of 196.4B. Regarding current trading prices, IVA is priced at $5.16, while NVO trades at $44.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas NVO's P/E ratio is 10.38. In terms of profitability, IVA's ROE is +18.38%, compared to NVO's ROE of +0.66%. Regarding short-term risk, IVA is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check NVO's competition here
IVA vs VRTX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, VRTX has a market cap of 110.6B. Regarding current trading prices, IVA is priced at $5.16, while VRTX trades at $435.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas VRTX's P/E ratio is 25.86. In terms of profitability, IVA's ROE is +18.38%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, IVA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check VRTX's competition here
IVA vs VRNA Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IVA is priced at $5.16, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IVA's ROE is +18.38%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, IVA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check VRNA's competition here
IVA vs REGN Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, REGN has a market cap of 65.4B. Regarding current trading prices, IVA is priced at $5.16, while REGN trades at $634.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas REGN's P/E ratio is 15.50. In terms of profitability, IVA's ROE is +18.38%, compared to REGN's ROE of +0.14%. Regarding short-term risk, IVA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check REGN's competition here
IVA vs ARGX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ARGX has a market cap of 50B. Regarding current trading prices, IVA is priced at $5.16, while ARGX trades at $808.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ARGX's P/E ratio is 35.93. In terms of profitability, IVA's ROE is +18.38%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, IVA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ARGX's competition here
IVA vs SGEN Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IVA is priced at $5.16, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IVA's ROE is +18.38%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IVA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check SGEN's competition here
IVA vs ALNY Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ALNY has a market cap of 39.5B. Regarding current trading prices, IVA is priced at $5.16, while ALNY trades at $295.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ALNY's P/E ratio is 74.08. In terms of profitability, IVA's ROE is +18.38%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, IVA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ALNY's competition here
IVA vs RVMD Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, RVMD has a market cap of 32.9B. Regarding current trading prices, IVA is priced at $5.16, while RVMD trades at $154.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas RVMD's P/E ratio is -21.76. In terms of profitability, IVA's ROE is +18.38%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, IVA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RVMD's competition here
IVA vs UTHR Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, UTHR has a market cap of 24.6B. Regarding current trading prices, IVA is priced at $5.16, while UTHR trades at $578.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas UTHR's P/E ratio is 21.39. In terms of profitability, IVA's ROE is +18.38%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IVA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check UTHR's competition here
IVA vs INSM Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, INSM has a market cap of 23.6B. Regarding current trading prices, IVA is priced at $5.16, while INSM trades at $108.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas INSM's P/E ratio is -18.90. In terms of profitability, IVA's ROE is +18.38%, compared to INSM's ROE of -1.30%. Regarding short-term risk, IVA is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check INSM's competition here
IVA vs BNTX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, BNTX has a market cap of 23.3B. Regarding current trading prices, IVA is priced at $5.16, while BNTX trades at $92.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas BNTX's P/E ratio is -15.64. In terms of profitability, IVA's ROE is +18.38%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, IVA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check BNTX's competition here
IVA vs RPRX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, RPRX has a market cap of 23.2B. Regarding current trading prices, IVA is priced at $5.16, while RPRX trades at $53.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas RPRX's P/E ratio is 28.35. In terms of profitability, IVA's ROE is +18.38%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, IVA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RPRX's competition here
IVA vs ROIV Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ROIV has a market cap of 21.3B. Regarding current trading prices, IVA is priced at $5.16, while ROIV trades at $29.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ROIV's P/E ratio is -54.94. In terms of profitability, IVA's ROE is +18.38%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, IVA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ROIV's competition here
IVA vs BGNE Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IVA is priced at $5.16, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IVA's ROE is +18.38%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, IVA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check BGNE's competition here
IVA vs INCY Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, INCY has a market cap of 19.4B. Regarding current trading prices, IVA is priced at $5.16, while INCY trades at $97.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas INCY's P/E ratio is 13.71. In terms of profitability, IVA's ROE is +18.38%, compared to INCY's ROE of +0.29%. Regarding short-term risk, IVA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check INCY's competition here
IVA vs DNA-WT Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IVA is priced at $5.16, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IVA's ROE is +18.38%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, IVA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check DNA-WT's competition here
IVA vs MRNA Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, MRNA has a market cap of 18.7B. Regarding current trading prices, IVA is priced at $5.16, while MRNA trades at $47.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas MRNA's P/E ratio is -5.78. In terms of profitability, IVA's ROE is +18.38%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, IVA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check MRNA's competition here
IVA vs GMAB Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, GMAB has a market cap of 16.5B. Regarding current trading prices, IVA is priced at $5.16, while GMAB trades at $26.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas GMAB's P/E ratio is 20.53. In terms of profitability, IVA's ROE is +18.38%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, IVA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check GMAB's competition here
IVA vs NBIX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, NBIX has a market cap of 15.7B. Regarding current trading prices, IVA is priced at $5.16, while NBIX trades at $155.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas NBIX's P/E ratio is 23.98. In terms of profitability, IVA's ROE is +18.38%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, IVA is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check NBIX's competition here
IVA vs JAZZ Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, JAZZ has a market cap of 14.9B. Regarding current trading prices, IVA is priced at $5.16, while JAZZ trades at $237.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas JAZZ's P/E ratio is 1978.25. In terms of profitability, IVA's ROE is +18.38%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, IVA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check JAZZ's competition here
IVA vs ASND Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, IVA is priced at $5.16, while ASND trades at $239.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ASND's P/E ratio is 27.26. In terms of profitability, IVA's ROE is +18.38%, compared to ASND's ROE of -56.42%. Regarding short-term risk, IVA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ASND's competition here
IVA vs BBIO Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, BBIO has a market cap of 13.3B. Regarding current trading prices, IVA is priced at $5.16, while BBIO trades at $67.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas BBIO's P/E ratio is -18.11. In terms of profitability, IVA's ROE is +18.38%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, IVA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check BBIO's competition here
IVA vs SMMT Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, SMMT has a market cap of 13.2B. Regarding current trading prices, IVA is priced at $5.16, while SMMT trades at $17.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas SMMT's P/E ratio is -10.69. In terms of profitability, IVA's ROE is +18.38%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, IVA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check SMMT's competition here
IVA vs KRTX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IVA is priced at $5.16, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IVA's ROE is +18.38%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IVA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check KRTX's competition here
IVA vs EXEL Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, EXEL has a market cap of 12.6B. Regarding current trading prices, IVA is priced at $5.16, while EXEL trades at $49.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas EXEL's P/E ratio is 16.57. In terms of profitability, IVA's ROE is +18.38%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, IVA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check EXEL's competition here
IVA vs IONS Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, IONS has a market cap of 12.6B. Regarding current trading prices, IVA is priced at $5.16, while IONS trades at $76.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas IONS's P/E ratio is -37.85. In terms of profitability, IVA's ROE is +18.38%, compared to IONS's ROE of -0.59%. Regarding short-term risk, IVA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check IONS's competition here
IVA vs MDGL Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, IVA is priced at $5.16, while MDGL trades at $524.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas MDGL's P/E ratio is -38.81. In terms of profitability, IVA's ROE is +18.38%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, IVA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check MDGL's competition here
IVA vs AXSM Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, AXSM has a market cap of 12.1B. Regarding current trading prices, IVA is priced at $5.16, while AXSM trades at $234.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas AXSM's P/E ratio is -62.79. In terms of profitability, IVA's ROE is +18.38%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, IVA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check AXSM's competition here
IVA vs RNAM Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IVA is priced at $5.16, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IVA's ROE is +18.38%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IVA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RNAM's competition here
IVA vs ARWR Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ARWR has a market cap of 11.1B. Regarding current trading prices, IVA is priced at $5.16, while ARWR trades at $78.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ARWR's P/E ratio is -34.66. In terms of profitability, IVA's ROE is +18.38%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, IVA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check ARWR's competition here
IVA vs BMRN Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, BMRN has a market cap of 10.2B. Regarding current trading prices, IVA is priced at $5.16, while BMRN trades at $52.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas BMRN's P/E ratio is 38.04. In terms of profitability, IVA's ROE is +18.38%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, IVA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check BMRN's competition here
IVA vs RXDX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IVA is priced at $5.16, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IVA's ROE is +18.38%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IVA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RXDX's competition here
IVA vs CYTK Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CYTK has a market cap of 9.5B. Regarding current trading prices, IVA is priced at $5.16, while CYTK trades at $76.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CYTK's P/E ratio is -11.14. In terms of profitability, IVA's ROE is +18.38%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, IVA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CYTK's competition here
IVA vs KRYS Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, IVA is priced at $5.16, while KRYS trades at $302.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas KRYS's P/E ratio is 40.47. In terms of profitability, IVA's ROE is +18.38%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IVA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check KRYS's competition here
IVA vs IMGN Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IVA is priced at $5.16, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IVA's ROE is +18.38%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IVA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check IMGN's competition here
IVA vs BPMC Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IVA is priced at $5.16, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IVA's ROE is +18.38%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, IVA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check BPMC's competition here
IVA vs IBRX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, IVA is priced at $5.16, while IBRX trades at $7.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas IBRX's P/E ratio is -9.31. In terms of profitability, IVA's ROE is +18.38%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, IVA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check IBRX's competition here
IVA vs ABVX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ABVX has a market cap of 8.3B. Regarding current trading prices, IVA is priced at $5.16, while ABVX trades at $126.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ABVX's P/E ratio is -23.55. In terms of profitability, IVA's ROE is +18.38%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, IVA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check ABVX's competition here
IVA vs CERE Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IVA is priced at $5.16, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CERE's P/E ratio is -16.47. In terms of profitability, IVA's ROE is +18.38%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IVA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CERE's competition here
IVA vs HALO Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, IVA is priced at $5.16, while HALO trades at $68.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas HALO's P/E ratio is 24.11. In terms of profitability, IVA's ROE is +18.38%, compared to HALO's ROE of +1.26%. Regarding short-term risk, IVA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check HALO's competition here
IVA vs NUVL Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, IVA is priced at $5.16, while NUVL trades at $104.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas NUVL's P/E ratio is -17.32. In terms of profitability, IVA's ROE is +18.38%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, IVA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check NUVL's competition here
IVA vs TECH Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, TECH has a market cap of 7.5B. Regarding current trading prices, IVA is priced at $5.16, while TECH trades at $47.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas TECH's P/E ratio is 68.53. In terms of profitability, IVA's ROE is +18.38%, compared to TECH's ROE of +0.05%. Regarding short-term risk, IVA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check TECH's competition here
IVA vs MTSR Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IVA is priced at $5.16, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IVA's ROE is +18.38%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, IVA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check MTSR's competition here
IVA vs PRAX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, PRAX has a market cap of 7.4B. Regarding current trading prices, IVA is priced at $5.16, while PRAX trades at $350.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas PRAX's P/E ratio is -26.16. In terms of profitability, IVA's ROE is +18.38%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, IVA is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check PRAX's competition here
IVA vs PCVX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, PCVX has a market cap of 7.2B. Regarding current trading prices, IVA is priced at $5.16, while PCVX trades at $50.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas PCVX's P/E ratio is -7.27. In terms of profitability, IVA's ROE is +18.38%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, IVA is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check PCVX's competition here
IVA vs IMVT Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, IVA is priced at $5.16, while IMVT trades at $33.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas IMVT's P/E ratio is -12.21. In terms of profitability, IVA's ROE is +18.38%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, IVA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check IMVT's competition here
IVA vs MRUS Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IVA is priced at $5.16, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IVA's ROE is +18.38%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, IVA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check MRUS's competition here
IVA vs ACLX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IVA is priced at $5.16, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ACLX's P/E ratio is -28.27. In terms of profitability, IVA's ROE is +18.38%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IVA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ACLX's competition here
IVA vs KYMR Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, KYMR has a market cap of 6.6B. Regarding current trading prices, IVA is priced at $5.16, while KYMR trades at $80.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas KYMR's P/E ratio is -22.56. In terms of profitability, IVA's ROE is +18.38%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, IVA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check KYMR's competition here
IVA vs RETA Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IVA is priced at $5.16, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas RETA's P/E ratio is -66.29. In terms of profitability, IVA's ROE is +18.38%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IVA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RETA's competition here
IVA vs CELC Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CELC has a market cap of 6.5B. Regarding current trading prices, IVA is priced at $5.16, while CELC trades at $134.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CELC's P/E ratio is -34.51. In terms of profitability, IVA's ROE is +18.38%, compared to CELC's ROE of -2.45%. Regarding short-term risk, IVA is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CELC's competition here
IVA vs CORT Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CORT has a market cap of 6.5B. Regarding current trading prices, IVA is priced at $5.16, while CORT trades at $60.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CORT's P/E ratio is 172.46. In terms of profitability, IVA's ROE is +18.38%, compared to CORT's ROE of +0.08%. Regarding short-term risk, IVA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CORT's competition here
IVA vs PTGX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, PTGX has a market cap of 6.4B. Regarding current trading prices, IVA is priced at $5.16, while PTGX trades at $99.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas PTGX's P/E ratio is -55.24. In terms of profitability, IVA's ROE is +18.38%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, IVA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check PTGX's competition here
IVA vs ALKS Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ALKS has a market cap of 6.2B. Regarding current trading prices, IVA is priced at $5.16, while ALKS trades at $37.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ALKS's P/E ratio is 41.50. In terms of profitability, IVA's ROE is +18.38%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, IVA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ALKS's competition here
IVA vs SRRK Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, SRRK has a market cap of 6.2B. Regarding current trading prices, IVA is priced at $5.16, while SRRK trades at $51.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas SRRK's P/E ratio is -14.93. In terms of profitability, IVA's ROE is +18.38%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, IVA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check SRRK's competition here
IVA vs RYTM Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, IVA is priced at $5.16, while RYTM trades at $89.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas RYTM's P/E ratio is -28.70. In terms of profitability, IVA's ROE is +18.38%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, IVA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RYTM's competition here
IVA vs CNTA Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, IVA is priced at $5.16, while CNTA trades at $39.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CNTA's P/E ratio is -22.35. In terms of profitability, IVA's ROE is +18.38%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, IVA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CNTA's competition here
IVA vs TGTX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, TGTX has a market cap of 6.1B. Regarding current trading prices, IVA is priced at $5.16, while TGTX trades at $39.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas TGTX's P/E ratio is 13.89. In terms of profitability, IVA's ROE is +18.38%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, IVA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check TGTX's competition here
IVA vs COGT Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, COGT has a market cap of 5.8B. Regarding current trading prices, IVA is priced at $5.16, while COGT trades at $33.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas COGT's P/E ratio is -15.64. In terms of profitability, IVA's ROE is +18.38%, compared to COGT's ROE of -0.83%. Regarding short-term risk, IVA is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check COGT's competition here
IVA vs BLTE Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, BLTE has a market cap of 5.7B. Regarding current trading prices, IVA is priced at $5.16, while BLTE trades at $142.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas BLTE's P/E ratio is -55.91. In terms of profitability, IVA's ROE is +18.38%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, IVA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check BLTE's competition here
IVA vs CDTX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IVA is priced at $5.16, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IVA's ROE is +18.38%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, IVA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CDTX's competition here
IVA vs PTCT Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, IVA is priced at $5.16, while PTCT trades at $67.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas PTCT's P/E ratio is -26.63. In terms of profitability, IVA's ROE is +18.38%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, IVA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check PTCT's competition here
IVA vs ABCM Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IVA is priced at $5.16, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IVA's ROE is +18.38%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IVA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ABCM's competition here
IVA vs ISEE Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IVA is priced at $5.16, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IVA's ROE is +18.38%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IVA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ISEE's competition here
IVA vs LEGN Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, LEGN has a market cap of 5.5B. Regarding current trading prices, IVA is priced at $5.16, while LEGN trades at $29.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas LEGN's P/E ratio is -21.40. In terms of profitability, IVA's ROE is +18.38%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, IVA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check LEGN's competition here
IVA vs CGON Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CGON has a market cap of 5.5B. Regarding current trading prices, IVA is priced at $5.16, while CGON trades at $61.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CGON's P/E ratio is -26.41. In terms of profitability, IVA's ROE is +18.38%, compared to CGON's ROE of -0.23%. Regarding short-term risk, IVA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check CGON's competition here
IVA vs LQDA Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, LQDA has a market cap of 5.3B. Regarding current trading prices, IVA is priced at $5.16, while LQDA trades at $60.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas LQDA's P/E ratio is 353.50. In terms of profitability, IVA's ROE is +18.38%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, IVA is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check LQDA's competition here
IVA vs APLS Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, IVA is priced at $5.16, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas APLS's P/E ratio is 38.35. In terms of profitability, IVA's ROE is +18.38%, compared to APLS's ROE of +0.40%. Regarding short-term risk, IVA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check APLS's competition here
IVA vs FBIOX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, IVA is priced at $5.16, while FBIOX trades at $25.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas FBIOX's P/E ratio is N/A. In terms of profitability, IVA's ROE is +18.38%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, IVA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check FBIOX's competition here
IVA vs APGE Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, IVA is priced at $5.16, while APGE trades at $82.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas APGE's P/E ratio is -19.12. In terms of profitability, IVA's ROE is +18.38%, compared to APGE's ROE of -0.33%. Regarding short-term risk, IVA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check APGE's competition here
IVA vs CRSP Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, IVA is priced at $5.16, while CRSP trades at $51.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CRSP's P/E ratio is -8.36. In terms of profitability, IVA's ROE is +18.38%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, IVA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CRSP's competition here
IVA vs MIRM Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, MIRM has a market cap of 5B. Regarding current trading prices, IVA is priced at $5.16, while MIRM trades at $98.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas MIRM's P/E ratio is -7.27. In terms of profitability, IVA's ROE is +18.38%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, IVA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check MIRM's competition here
IVA vs TERN Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, IVA is priced at $5.16, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas TERN's P/E ratio is -51.41. In terms of profitability, IVA's ROE is +18.38%, compared to TERN's ROE of -0.20%. Regarding short-term risk, IVA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check TERN's competition here
IVA vs LGND Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, LGND has a market cap of 4.7B. Regarding current trading prices, IVA is priced at $5.16, while LGND trades at $235.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas LGND's P/E ratio is 30.72. In terms of profitability, IVA's ROE is +18.38%, compared to LGND's ROE of +0.16%. Regarding short-term risk, IVA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check LGND's competition here
IVA vs FOLD Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IVA is priced at $5.16, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas FOLD's P/E ratio is -161.00. In terms of profitability, IVA's ROE is +18.38%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IVA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check FOLD's competition here
IVA vs AKRO Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IVA is priced at $5.16, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IVA's ROE is +18.38%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, IVA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check AKRO's competition here
IVA vs ALPN Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IVA is priced at $5.16, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IVA's ROE is +18.38%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IVA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ALPN's competition here
IVA vs SYRE Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, IVA is priced at $5.16, while SYRE trades at $73.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas SYRE's P/E ratio is -34.72. In terms of profitability, IVA's ROE is +18.38%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, IVA is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check SYRE's competition here
IVA vs CAI Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, IVA is priced at $5.16, while CAI trades at $15.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CAI's P/E ratio is -5.62. In terms of profitability, IVA's ROE is +18.38%, compared to CAI's ROE of +0.06%. Regarding short-term risk, IVA is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CAI's competition here
IVA vs MANE Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, IVA is priced at $5.16, while MANE trades at $102.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas MANE's P/E ratio is -38.68. In terms of profitability, IVA's ROE is +18.38%, compared to MANE's ROE of -0.95%. Regarding short-term risk, IVA is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check MANE's competition here
IVA vs XENE Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, IVA is priced at $5.16, while XENE trades at $53.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas XENE's P/E ratio is -11.49. In terms of profitability, IVA's ROE is +18.38%, compared to XENE's ROE of -0.49%. Regarding short-term risk, IVA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check XENE's competition here
IVA vs OPT Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IVA is priced at $5.16, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas OPT's P/E ratio is -1.52. In terms of profitability, IVA's ROE is +18.38%, compared to OPT's ROE of +0.88%. Regarding short-term risk, IVA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check OPT's competition here
IVA vs NAMS Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, NAMS has a market cap of 4.2B. Regarding current trading prices, IVA is priced at $5.16, while NAMS trades at $36.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas NAMS's P/E ratio is -20.29. In terms of profitability, IVA's ROE is +18.38%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, IVA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check NAMS's competition here
IVA vs TVTX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, TVTX has a market cap of 4.1B. Regarding current trading prices, IVA is priced at $5.16, while TVTX trades at $44.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas TVTX's P/E ratio is -88.58. In terms of profitability, IVA's ROE is +18.38%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, IVA is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check TVTX's competition here
IVA vs MRTX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IVA is priced at $5.16, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IVA's ROE is +18.38%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IVA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check MRTX's competition here
IVA vs KNSA Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, KNSA has a market cap of 4B. Regarding current trading prices, IVA is priced at $5.16, while KNSA trades at $52.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas KNSA's P/E ratio is 58.03. In terms of profitability, IVA's ROE is +18.38%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, IVA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check KNSA's competition here
IVA vs CRNX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, IVA is priced at $5.16, while CRNX trades at $36.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CRNX's P/E ratio is -7.16. In terms of profitability, IVA's ROE is +18.38%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, IVA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CRNX's competition here
IVA vs CPRX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, IVA is priced at $5.16, while CPRX trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CPRX's P/E ratio is 18.11. In terms of profitability, IVA's ROE is +18.38%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IVA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CPRX's competition here
IVA vs RYZB Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IVA is priced at $5.16, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IVA's ROE is +18.38%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IVA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RYZB's competition here
IVA vs CBAY Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IVA is priced at $5.16, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IVA's ROE is +18.38%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IVA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CBAY's competition here
IVA vs ACAD Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, IVA is priced at $5.16, while ACAD trades at $21.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ACAD's P/E ratio is 9.62. In terms of profitability, IVA's ROE is +18.38%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, IVA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ACAD's competition here
IVA vs DNTH Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, IVA is priced at $5.16, while DNTH trades at $86.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas DNTH's P/E ratio is -20.52. In terms of profitability, IVA's ROE is +18.38%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, IVA is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check DNTH's competition here
IVA vs EWTX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, IVA is priced at $5.16, while EWTX trades at $33.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas EWTX's P/E ratio is -20.22. In terms of profitability, IVA's ROE is +18.38%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, IVA is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check EWTX's competition here
IVA vs ERAS Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, ERAS has a market cap of 3.6B. Regarding current trading prices, IVA is priced at $5.16, while ERAS trades at $11.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas ERAS's P/E ratio is -12.37. In terms of profitability, IVA's ROE is +18.38%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, IVA is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ERAS's competition here
IVA vs VKTX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, IVA is priced at $5.16, while VKTX trades at $30.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas VKTX's P/E ratio is -7.42. In terms of profitability, IVA's ROE is +18.38%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, IVA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check VKTX's competition here
IVA vs SWTX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IVA is priced at $5.16, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IVA's ROE is +18.38%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, IVA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check SWTX's competition here
IVA vs VCYT Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, VCYT has a market cap of 3.5B. Regarding current trading prices, IVA is priced at $5.16, while VCYT trades at $44.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas VCYT's P/E ratio is 40.94. In terms of profitability, IVA's ROE is +18.38%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, IVA is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check VCYT's competition here
IVA vs TLX Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, IVA is priced at $5.16, while TLX trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas TLX's P/E ratio is -478.50. In terms of profitability, IVA's ROE is +18.38%, compared to TLX's ROE of -0.02%. Regarding short-term risk, IVA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check TLX's competition here
IVA vs DNLI Comparison May 2026
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 268.2M. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, IVA is priced at $5.16, while DNLI trades at $19.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -2.33, whereas DNLI's P/E ratio is -6.73. In terms of profitability, IVA's ROE is +18.38%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, IVA is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check DNLI's competition here